GlaxoSmithKline fined $3 billion
GlaxoSmithKline was socked with $3 billion in fines by US authorities Monday over charges it marketed drugs for unauthorized uses, held back safety data, and cheated the government's Medicaid program. The Justice Department said GSK was fined over misbranding its drugs Paxil and Wellbutrin, and for holding back data while making unbacked claims for its diabetes drug Avandia. GSK pleaded guilty and agreed to the fines in what the department called the largest health care fraud settlement in US history.
Don't have any illusions: this is the Rule, not the Exception.
Blatant Lying about Psychoactive Drugs is calculated into the price of doing business.
Blatant Lying about Psychoactive Drugs is calculated into the price of doing business.
